My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

214.35 -0.67 (-0.31%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

92 93 Next >

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗

October 08, 2024

Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...

Via Benzinga

In-Depth Examination Of 11 Analyst Recommendations For AbbVie ↗

October 07, 2024

Via Benzinga

Biotech Stocks Poised For Another Big Move In Q4 ↗

October 07, 2024

The healthcare sector can be a safe haven if volatility increases.

Via Talk Markets

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

3 Magnificent Dividend Stocks to Buy in October ↗

October 06, 2024

These dividend stocks are great picks as the fall season gets underway.

Via The Motley Fool

Comparing AbbVie With Industry Competitors In Biotechnology Industry ↗

October 03, 2024

Via Benzinga

Behind the Scenes of AbbVie's Latest Options Trends ↗

October 03, 2024

Via Benzinga

(ABBV) - Analyzing AbbVie's Short Interest ↗

September 27, 2024

Via Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

September 26, 2024

Via Benzinga

Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You? ↗

October 06, 2024

Declining earnings haven't scared billionaire investors away from this stock.

Via The Motley Fool

2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now ↗

October 05, 2024

These companies can lend growth and dividend returns to a long-term investor's portfolio.

Via The Motley Fool

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

October 04, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

3 Industries Set To Explode When Interest Rates Drop ↗

October 03, 2024

Via Talk Markets

Behind the Scenes of AbbVie's Latest Options Trends ↗

September 24, 2024

Via Benzinga

Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗

September 20, 2024

Via Benzinga

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry ↗

September 19, 2024

Via Benzinga

Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal ↗

October 03, 2024

Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025.

Via Benzinga

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗

October 03, 2024

Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.

Via Benzinga

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗

October 03, 2024

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Via Investor's Business Daily

Topics Stocks

5 Best Dividend Growth Stocks to Buy in October ↗

October 02, 2024

These five stocks are known for their generous dividend programs and robust business models.

Via The Motley Fool

Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

October 01, 2024

Via Investor Brand Network

Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

October 01, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades' ↗

September 30, 2024

On CNBC's "Halftime Report Final Trades," Kevin Simpson of Capital Wealth Planning said Meta Platforms is hitting on all cylinders.

Via Benzinga

15 Best Dividend Stocks for Lifelong Passive Income ↗

September 30, 2024

These 15 dividend stocks can deliver stable passive income for life.

Via The Motley Fool

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential ↗

September 27, 2024

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...

Via Benzinga

AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease ↗

September 26, 2024

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and...

Via Benzinga

Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead ↗

September 26, 2024

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.

Via The Motley Fool

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years ↗

September 20, 2024

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again ↗

September 19, 2024

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

Via The Motley Fool

Topics Stocks

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.